1. How many patients have you treated (using surgery, radiotherapy or any systemic anti-cancer therapy) in the last three months for:
a. Breast cancer (any stage)
b. Early breast cancer (both early-stage and locally advanced, inclusive of stages I-IIIC)
c. Metastatic breast cancer (stage IV)
2. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
d. Atezolizumab +Nab-paclitaxel/Paclitaxel
e. Capecitabine as a single agent
f. Carboplatin or Cisplatin as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fluorouracil
j. Fulvestrant as a single agent
k. Lapatinib
l. Neratinib
m. Olaparib
n. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
o. Palbociclib + Fulvestrant
p. Pertuzumab + Trastuzumab + Docetaxel
q. Platinum (e.g. carboplatin or cisplatin) as a single agent
r. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
s. Ribociclib + Fulvestrant
t. Talazoparib
u. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
v. Transtuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Any other active systemic anti-cancer therapy

Download response Incidence and treatment of breast cancer. 110621